Call Options

18 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2024

Apr 19, 2024

SELL
$63.75 - $108.06 $1.38 Million - $2.33 Million
-21,600 Reduced 71.52%
8,600 $113,000
Q4 2023

Jan 18, 2024

BUY
$26.88 - $83.49 $602,112 - $1.87 Million
22,400 Added 287.18%
30,200 $817,000
Q3 2023

Nov 07, 2023

BUY
$29.46 - $36.61 $126,678 - $157,423
4,300 Added 122.86%
7,800 $11,000
Q2 2023

Jul 18, 2023

BUY
$32.62 - $40.75 $35,882 - $44,825
1,100 Added 45.83%
3,500 $12,000
Q1 2023

May 01, 2023

SELL
$33.36 - $45.71 $70,056 - $95,991
-2,100 Reduced 46.67%
2,400 $2,000
Q4 2022

Feb 07, 2023

BUY
$35.77 - $51.11 $85,848 - $122,664
2,400 Added 114.29%
4,500 $25,000
Q3 2022

Oct 25, 2022

SELL
$38.54 - $54.52 $242,802 - $343,476
-6,300 Reduced 75.0%
2,100 $30,000
Q2 2022

Aug 04, 2022

BUY
$33.93 - $48.92 $111,969 - $161,436
3,300 Added 64.71%
8,400 $26,000
Q1 2022

Apr 14, 2022

BUY
$29.74 - $46.0 $148,700 - $230,000
5,000 Added 5000.0%
5,100 $25,000
Q4 2021

Jan 18, 2022

SELL
$34.35 - $46.38 $456,855 - $616,854
-13,300 Reduced 99.25%
100 $2,000
Q3 2021

Oct 26, 2021

BUY
$18.54 - $35.74 $239,166 - $461,046
12,900 Added 2580.0%
13,400 $39,000
Q4 2020

Jan 21, 2021

BUY
$15.26 - $28.61 $6,104 - $11,444
400 Added 400.0%
500 $1,000
Q3 2020

Oct 27, 2020

SELL
$20.58 - $28.96 $37,044 - $52,128
-1,800 Reduced 94.74%
100 $0
Q2 2020

Jul 22, 2020

BUY
$11.15 - $24.64 $21,185 - $46,816
1,900 New
1,900 $9,000
Q3 2018

Nov 07, 2018

SELL
$6.4 - $9.85 $2,560 - $3,940
-400 Closed
0 $0
Q1 2018

May 11, 2018

SELL
$7.2 - $10.05 $31,680 - $44,220
-4,400 Reduced 91.67%
400 $0
Q4 2017

Jan 17, 2018

SELL
$7.25 - $15.65 $231,275 - $499,235
-31,900 Reduced 86.92%
4,800 $1,000
Q3 2017

Oct 17, 2017

BUY
$12.0 - $15.0 $440,400 - $550,500
36,700
36,700 $67,000

Others Institutions Holding CYTK

About CYTOKINETICS INC


  • Ticker CYTK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,144,096
  • Market Cap $4.57B
  • Description
  • Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...
More about CYTK
Track This Portfolio

Track Cutler Group LP Portfolio

Follow Cutler Group LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutler Group LP with notifications on news.